Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 8/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | TP53 | P04637 | 3/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | THRB | P10828 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL308812 | 0.88 | TSHR (0.63) | TSHRALDH1A1TP53HIF1ACYP3A4 | |
| SCHEMBL9637784 | 0.86 | TSHR (0.67) | TSHRALDH1A1TP53HIF1ACYP3A4 | |
| SCHEMBL29467782 | 0.85 | TSHR (0.54) | TSHRALDH1A1TP53HIF1ACYP3A4 | |
| Ammonia Solution, Strong SCHEMBL28181274 | 0.84 | TSHR (0.64) | TSHRALDH1A1TP53HIF1ACYP3A4 | |
| SCHEMBL7783389 | 0.83 | TSHR (0.52) | TSHRALDH1A1TP53HIF1ACYP3A4 | |
| SCHEMBL9805672 | 0.83 | TSHR (0.52) | TSHRALDH1A1TP53HIF1ACYP3A4 | |
| SCHEMBL7698331 | 0.83 | TSHR (0.52) | TSHRALDH1A1TP53HIF1ACYP3A4 | |
| Hydrochloric Acid SCHEMBL28821608 | 0.83 | TSHR (0.62) | TSHRALDH1A1TP53HIF1ACYP3A4 | |
| SCHEMBL11030891 | 0.82 | ATM (0.52) | TSHRALDH1A1TP53HIF1ACYP3A4 | |
| SCHEMBL674051 | 0.82 | TSHR (0.50) | TSHRALDH1A1TP53HIF1ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111883748-A | Method for coating oxide film on surface of lithium ion battery anode powder material | 华南理工大学 | 2020-11-03 | — | — | CN | claimed |
| CN-111883748-A | Method for coating oxide film on surface of lithium ion battery anode powder material | 华南理工大学 | 2020-11-03 | — | — | CN | disclosed |
| EP-3186226-B1 | OXIME SULFONATE DERIVATIVES | BASF SE (DE) | 2020-06-17 | — | — | EP | disclosed |
| US-20190171099-A1 | POLYMERIZABLE COMPOSITION COMPRISING AN OXIME SULFONATE AS THERMAL CURING AGENT | BASF SE (DE) | 2019-06-06 | — | — | US | disclosed |
| US-10241399-B2 | Polymerizable composition comprising an oxime sulfonate as thermal curing agent | BASF SE (DE) | 2019-03-26 | — | — | US | disclosed |
| EP-2668156-B1 | POLYMERIZABLE COMPOSITION COMPRISING AN OXIME SULFONATE AS THERMAL CURING AGENT | BASF SE (DE) | 2018-10-31 | — | — | EP | disclosed |
| US-20170260132-A1 | OXIME SULFONATE DERIVATIVES | BASF SE (DE) | 2017-09-14 | — | — | US | disclosed |
| EP-3186226-A1 | OXIME SULFONATE DERIVATIVES | BASF SE (DE) | 2017-07-05 | — | — | EP | disclosed |
| US-9310677-B2 | Polymerizable composition comprising an oxime sulfonate as thermal curing agent | BASF (DE) | 2016-04-12 | — | — | US | disclosed |
| WO-2016030790-A1 | OXIME SULFONATE DERIVATIVES | BASF SE (DE) | 2016-03-03 | — | — | WO | disclosed |
| WO-2007078819-A2 | LOW SURFACE ENERGY BLOCK CO-POLYMER PREPARATION METHODS AND APPLICATIONS | ARKEMA INC. (US) | 2007-07-12 | — | — | WO | disclosed |
| US-20060128903-A1 | Process for the controlled increase in the molecular weight of polyethylenes | ROTH MICHAEL | 2006-06-15 | — | — | US | disclosed |
| EP-1655303-A2 | Hydroxylamine esters as polimerization initiators | Ciba SC Holding AG (CH) | 2006-05-10 | — | — | EP | disclosed |
| US-7030196-B2 | Process for reducing the molecular weight of polypropylene | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 2006-04-18 | — | — | US | disclosed |
| US-20030216494-A1 | Hydroxylamine esters as polymerization initiators | CIBA SPECIALTY CHEMICALS CORP. | 2003-11-20 | — | — | US | disclosed |
| CN-1333790-A | pigment composition containing ATRP polymers | CIBA SPEICALTY CHEMICALS HOLDI (CH) | 2002-01-30 | — | — | CN | disclosed |
| EP-0273457-B1 | ANTIFOULING PAINT | NIPPON OIL AND FATS COMPANY, LIMITED (JP) | 1992-07-08 | — | — | EP | disclosed |
| US-4898895-A | Antifouling pain having a polyacrylate component with pendent silyl or siloxane groups | NIPPON OIL AND FATS CO., LTD. (JP) | 1990-02-06 | — | — | US | disclosed |
| US-4883852-A | SILICON CONTAINING ACRYLIC ESTER POLYMER, POLYSILOXANES | NIPPON OIL AND FATS CO., LTD. (JP) | 1989-11-28 | — | — | US | disclosed |
| EP-0273457-A2 | Antifouling paint | NIPPON OIL AND FATS COMPANY, LIMITED (JP) | 1988-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10241399-B2 | Polymerizable composition comprising an oxime sulfonate as thermal curing agent | SULT1E1, COX6B1, SULT1A1 | TSHR 3974/4885ALDH1A1 776/4885TP53 4571/4885 |
| US-20170260132-A1 | OXIME SULFONATE DERIVATIVES | CBR3, CBR1, C1R | TSHR 132/4885ALDH1A1 1495/4885TP53 2732/4885 |
| US-20030216494-A1 | Hydroxylamine esters as polymerization initiators | PNMT, HPGDS, HAAO | TSHR 2473/4885ALDH1A1 941/4885TP53 3116/4885 |
| US-20190171099-A1 | POLYMERIZABLE COMPOSITION COMPRISING AN OXIME SULFONATE AS THERMAL CURING AGENT | SULT1E1, COX6B1, SULT1A1 | TSHR 3974/4885ALDH1A1 776/4885TP53 4571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.